Research indicates that 15% of patients discontinuing antidepressants suffer from withdrawal symptoms, with 3% experiencing severe effects. This contrasts with earlier studies showing higher incidences, suggesting the influence of the nocebo effect and expectations.
About 15% of individuals stopping antidepressants face discontinuation symptoms, with severe cases in 3%. This data, from a review of 79 trials, highlights the potential impact of the nocebo effect and stresses the importance of monitored medication withdrawal.
- The first meta-analysis on the incidence of antidepressant discontinuation symptoms includes data from over 20,000 patients gathered from 79 randomized controlled trials and observational studies.
- Overall, approximately one in three patients reported a discontinuation symptom but the new study aimed to distinguish between symptoms directly caused by stopping medication, and other ‘non-specific’ symptoms that may be associated with patients’ or practitioners’ expectations (the nocebo effect).
- Study concludes that one in six to seven patients will experience one or more discontinuation symptoms directly caused by stopping the medication, and one in 35 will likely experience severe symptoms.
- Authors highlight that plans to discontinue an antidepressant should be made jointly with patients and doctors, and that patients should be monitored and supported, particularly patients who develop severe symptoms and may be at risk of disengaging from care.
Discontinuation Symptoms in Antidepressant Withdrawal
For someone stopping taking antidepressants, the risk of experiencing one or more discontinuation symptoms (also called withdrawal symptoms), such as dizziness, headache, nausea, insomnia, and irritability, due directly to stopping the medication is 15% (equivalent to one in six to seven people), according to a systematic review and meta-analysis published in DOI: 10.1016/S2215-0366(24)00133-0



















Discussion about this post